Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT).

@article{Jacques2012RelationshipOC,
  title={Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT).},
  author={Richard M Jacques and Steven Boonen and Felicia Cosman and Ian R Reid and Doug Bauer and Donald M. Black and Richard Eastell},
  journal={Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research},
  year={2012},
  volume={27 8},
  pages={
          1627-34
        }
}
Measurements of change in bone mineral density (BMD) are thought to be weak predictors of treatment effect on the reduction of fracture risk. In this study we report an alternative year-on-year approach for the estimation of treatment effect explained by BMD in which we examine the relationship between fracture risk and the most recent change in BMD. We studied 7736 postmenopausal women (ages 65 to 89 years) who were participants in the Health Outcomes and Reduced Incidence with Zoledronic Acid… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 46 CITATIONS

Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data.

  • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 2016
VIEW 6 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

Bone strength and surrogate markers: the first, second, and third fiddle.

  • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 2012
VIEW 3 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 18 REFERENCES

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

  • The New England journal of medicine
  • 2007
VIEW 9 EXCERPTS
HIGHLY INFLUENTIAL

Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis.

  • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 2009
VIEW 2 EXCERPTS

Similar Papers